Medicare Enrolled
Dr. Christopher Lucasti, DO FACOI
Infectious Disease · Somers Point, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lucasti from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lucasti?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lucasti
Dr. Christopher Lucasti is an infectious disease specialist in Somers Point, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lucasti performed 112,748 Medicare services across 2,156 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lucasti received a total of $119,397 from 57 pharmaceutical and/or device companies across 958 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lucasti is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in NJ
$119,397 industry payments
Medicare Practice Summary
Medicare Utilization ↗112,748
Medicare services
Top 0% in NJ for infectious disease
2,156
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,637 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daptomycin antibiotic injection | 95,170 | $0 | $0 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
6,468 | $0 | $16 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
1,870 | $55 | $276 |
| Injection, cefepime hydrochloride, 500 mg | 1,806 | $1 | $10 |
| Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 1,785 | $1 | $9 |
| Vancomycin injection, 500 mg A 500 mg dose of vancomycin antibiotic is administered via injection. |
1,365 | $2 | $17 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
941 | $65 | $103 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
735 | $10 | $98 |
| Refilling and maintenance of portable pump This service involves refilling and performing maintenance on a portable pump. |
581 | $111 | $580 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
373 | $143 | $291 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
334 | $72 | $99 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
296 | $103 | $145 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
225 | $98 | $150 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
179 | $25 | $126 |
| New patient office visit, complex (60-74 min) | 158 | $177 | $272 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
155 | $30 | $65 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
73 | $61 | $102 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
61 | $17 | $77 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
57 | $141 | $216 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
56 | $106 | $198 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
16 | $141 | $200 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
16 | $39 | $57 |
| Recombinant quadrivalent influenza vaccine A flu shot that protects against four strains of influenza virus. It is produced using recombinant DNA technology rather than growing the virus in eggs. |
14 | $67 | $75 |
| Initial nursing facility care, moderate complexity Initial care provided to a patient in a nursing facility with moderate medical decision making, taking at least 35 minutes. |
14 | $108 | $189 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.9% high complexity
95.2% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$119,397
Total received (2018-2024)
Avg $17,057/year across 7 years
Top 2% in NJ for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
958
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$92,108 (77.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,200 (11.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$13,089 (11.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$15,791
2023
$21,461
2022
$9,988
2021
$14,997
2020
$9,796
2019
$23,354
2018
$24,011
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$13,642
ViiV Healthcare Company
$498
Theratechnologies Inc.
$249
ABBVIE INC.
$228
Cerapedics Inc.
$191
Merck Sharp & Dohme LLC
$119
Paratek Pharmaceuticals, Inc.
$104
Insmed, Inc.
$95
PFIZER INC.
$81
Cumberland Pharmaceuticals, Inc.
$71
Smith+Nephew, Inc.
$66
AIMMUNE THERAPEUTICS, INC.
$55
Takeda Pharmaceuticals U.S.A., Inc.
$45
Philips North America LLC
$39
Shionogi Inc
$34
Grifols USA, LLC
$31
EMD Serono, Inc.
$31
Napo Pharmaceuticals Inc
$30
CSL Behring
$30
Pharming Healthcare, Inc.
$29
Ferring Pharmaceuticals Inc.
$24
Organogenesis Inc.
$24
Novo Nordisk Inc
$22
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$18
La Jolla Pharmaceutical Company
$18
Solventum Corporation
$14
Top 3 companies account for 91.1% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$81,625
Allergan Inc.
$14,509
ViiV Healthcare Company
$6,387
Allergan, Inc.
$3,302
Alphatec Spine, Inc
$1,668
Theratechnologies Inc.
$1,650
Merck Sharp & Dohme Corporation
$950
Janssen Biotech, Inc.
$851
CIPLA USA INC.
$778
Globus Medical, Inc.
$671
ABBVIE INC.
$526
Musculoskeletal Transplant Foundation Inc.
$521
EMD Serono, Inc.
$460
Cumberland Pharmaceuticals, Inc.
$445
Merck Sharp & Dohme LLC
$437
Insmed, Inc.
$420
Janssen Products, LP
$369
Smith+Nephew, Inc.
$293
Napo Pharmaceuticals Inc
$291
La Jolla Pharmaceutical Company
$253
Paratek Pharmaceuticals, Inc.
$245
Octapharma USA, Inc.
$241
Melinta Therapeutics, Inc.
$231
AbbVie Inc.
$225
Cerapedics Inc.
$191
Innovation Technologies Inc
$153
AbbVie, Inc.
$148
Philips Electronics North America Corporation
$141
Melinta Therapeutics, LLC
$135
Organogenesis Inc.
$119
Integra LifeSciences Corporation
$118
PFIZER INC.
$116
Shionogi Inc
$84
Takeda Pharmaceuticals U.S.A., Inc.
$81
GlaxoSmithKline, LLC.
$74
Ferring Pharmaceuticals Inc.
$72
Pharming Healthcare, Inc.
$60
Nabriva Therapeutics, plc
$59
AIMMUNE THERAPEUTICS, INC.
$55
Theravance Biopharma, Inc.
$45
Philips North America LLC
$39
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$38
Novo Nordisk Inc
$36
Vyera Pharmaceuticals, LLC
$34
Grifols USA, LLC
$31
CSL Behring
$30
Smith & Nephew, Inc.
$28
ORGANOGENESIS INC.
$27
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$18
TETRAPHASE PHARMACEUTICALS, INC.
$17
Daiichi Sankyo Inc.
$17
Sumitomo Pharma America, Inc.
$15
Sanofi Pasteur Inc.
$15
Solventum Corporation
$14
Oxford Immunotec USA Inc
$13
VBI Vaccines (Delaware) Inc.
$13
TISSUETECH, INC.
$12
Top 3 companies account for 85.9% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · APRETUDE · AVYCAZ · Apligraf · Arikayce · Baxdela · Biktarvy · CABENUVA · COLLAGENASE SANTYL · DALVANCE · DIFICID · DOVATO · Daraprim 30 Tablet in 1 Bottle · Daraprim Tablet 25mg · EGRIFTA · EGRIFTA SV · Excelsius Robotics System · FLUZONE HIGH-DOSE · Fetroja · GEMTESA · HYQVIA · Hizentra · I-FACTOR PEPTIDE ENHANCED BONE GRAFT · INJECTAFER · IRRISEPT · ISENTRESS · Integra · Invictus MIS · JULUCA · Kimyrsa · LifeVest · MAVYRET · Mavyret · Mytesi · NEOX · NOXAFIL · NUZYRA · OCTAGAM · OCTAGAM IMMUNE GLOBULIN (HUMAN) · Orbactiv · Other - Miscellaneous · PANZYGA · PIFELTRO · PREVNAR 20 · PREZCOBIX · Pico 14 · PreHevbrio · Puraply · REBYOTA · REGRANEX · RUCONEST · RUKOBIA · Rezzayo · SEROSTIM · SHINGRIX · SIVEXTRO · SYMTUZA · Santyl · Saxenda · Serostim · Symtuza · TEFLARO · TRIUMEQ · TROGARZO · TSPOT TB TEST · Truvada · UBRELVY · V.A.C.ULTA · VIBATIV · VOWST · Vabomere · Veklury · Vibativ · XACDURO · XERAVA · XIFAXAN · Xembify · Xenleta · Xerava · ZEMDRI (PLAZOMICIN)
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (77%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in infectious disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for infectious disease in NJ.
Geographic Context
Infectious diseases within 10 mi
8
Per 100K population
2.9
County median income
$76,819
Nearest hospital
SHORE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lucasti is a mixed practice specialist, with above-average Medicare volume (top 0% in NJ), with speaking/promotional industry engagement in the top 2% of NJ peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lucasti experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Lucasti performed 95,170 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lucasti receive payments from pharmaceutical companies?
Yes. Dr. Lucasti received a total of $119,397 from 57 companies across 958 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lucasti's costs compare to other infectious diseases in Somers Point?
Dr. Lucasti's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lucasti) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Somers Point
Browse infectious diseases in Somers Point ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in NJ
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in NJ
Which NJ infectious diseases receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Allergan Inc. Payments to Doctors
See all physicians who received payments from Allergan Inc.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology